Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Cash from Investing Activities (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Cash from Investing Activities for 7 consecutive years, with $16.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities rose 370.22% year-over-year to $16.4 million, compared with a TTM value of -$5.1 million through Dec 2025, down 129.32%, and an annual FY2025 reading of -$5.1 million, down 129.32% over the prior year.
  • Cash from Investing Activities was $16.4 million for Q4 2025 at aTYR PHARMA, up from -$20.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $20.6 million in Q3 2022 and bottomed at -$49.3 million in Q4 2021.
  • Average Cash from Investing Activities over 5 years is -$2.6 million, with a median of $321500.0 recorded in 2022.
  • The sharpest move saw Cash from Investing Activities crashed 1640.68% in 2021, then soared 791.35% in 2023.
  • Year by year, Cash from Investing Activities stood at -$49.3 million in 2021, then skyrocketed by 104.05% to $2.0 million in 2022, then surged by 791.35% to $17.8 million in 2023, then crashed by 134.15% to -$6.1 million in 2024, then surged by 370.22% to $16.4 million in 2025.
  • Business Quant data shows Cash from Investing Activities for ATYR at $16.4 million in Q4 2025, -$20.4 million in Q3 2025, and $3.3 million in Q2 2025.